|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bozovic-Spasojevic I, Azambuja E,
McCaskill-Stevens W, Dinh P and Cardoso F: Chemoprevention for
breast cancer. Cancer Treat Rev. 38:329–339. 2012. View Article : Google Scholar
|
|
3
|
Zhang Y, Luo M, Zu Y, et al: Dryofragin, a
phloroglucinol derivative, induces apoptosis in human breast cancer
MCF-7 cells through ROS-mediated mitochondrial pathway. Chem Biol
Interact. 199:129–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krifa M, Pizzi A, Mousli M, Chekir-Ghedira
L, Leloup L and Ghedira K: Limoniastrum guyonianum aqueous gall
extract induces apoptosis in colorectal cancer cells by inhibiting
calpain activity. Tumour Biol. 35:7877–7885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ziech D, Anestopoulos I, Hanafi R, et al:
Pleiotrophic effects of natural products in ROS-induced
carcinogenesis: The role of plant-derived natural products in oral
cancer chemoprevention. Cancer Lett. 327:16–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Magee PJ, Owusu-Apenten R, McCann MJ, Gill
CI and Rowland IR: Chickpea (Cicer arietinum) and other
plant-derived protease inhibitor concentrates inhibit breast and
prostate cancer cell proliferation in vitro. Nutr Cancer.
64:741–748. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang Y, DeMarco VG and Nicholl MB:
Resveratrol enhances radiation sensitivity in prostate cancer by
inhibiting cell proliferation and promoting cell senescence and
apoptosis. Cancer Sci. 103:1090–1098. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q, Fan H, Liu Y, et al: Curcumin
enhances the radio-sensitivity in nasopharyngeal carcinoma cells
involving the reversal of differentially expressed long non-coding
RNAs. Int J Oncol. 44:858–864. 2014.PubMed/NCBI
|
|
9
|
Cragg GM and Newman DJ: Plants as a source
of anti-cancer agents. J Ethnopharmacol. 100:72–79. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Srivastava V, Negi AS, Kumar JK, Gupta MM
and Khanuja SP: Plant-based anticancer molecules: A chemical and
biological profile of some important leads. Bioorg Med Chem.
13:5892–5908. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kourounakis AP, Assimopoulou AN,
Papageorgiou VP, Gavalas A and Kourounakis PN: Alkannin and
shikonin: Effect on free radical processes and on inflammation - a
preliminary pharmacochemical investigation. Arch Pharm (Weinheim).
335:262–266. 2002. View Article : Google Scholar
|
|
12
|
Acharya BR, Bhattacharyya S, Choudhury D
and Chakrabarti G: The microtubule depolymerizing agent
naphthazarin induces both apoptosis and autophagy in A549 lung
cancer cells. Apoptosis. 16:924–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kundaković T, Stanojković T, Juranić Z and
Kovacević N: Cytotoxicity in vitro of naphthazarin derivatives from
onosma arenaria. Phytother Res. 20:602–604. 2006. View Article : Google Scholar
|
|
14
|
Johansson AC, Norberg-Spaak L and Roberg
K: Role of lysosomal cathepsins in naphthazarin- and fas-induced
apoptosis in oral squamous cell carcinoma cells. Acta Otolaryngol.
126:70–81. 2006. View Article : Google Scholar
|
|
15
|
Song GY, Kim Y, You YJ, Cho H, Kim SH, Sok
DE and Ahn BZ: Naphthazarin derivatives (VI): Synthesis, inhibitory
effect on DNA topoisomerase-I and antiproliferative activity of 2-
or 6-(1-oxyiminoalkyl)-5,8-dimethoxy-1,4-naphthoquinones. Arch
Pharm (Weinheim). 333:87–92. 2000. View Article : Google Scholar
|
|
16
|
Kim JA, Lee EK, Park SJ, Kim ND, Hyun DH,
Lee CG, Lee JH, Yang KM, Heo K and Son TG: Novel anti-cancer role
of naphthazarin in human gastric cancer cells. Int J Oncol.
40:157–162. 2012.
|
|
17
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee YH and Bae YS: Phospholipase D2
downregulation induces cellular senescence through a reactive
oxygen species-p53-p21Cip1/WAF1 pathway. FEBS Lett. 588:3251–3258.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saha K, Adhikary G, Kanade SR, Rorke EA
and Eckert RL: p38δ regulates p53 to control p21Cip1 expression in
human epidermal keratinocytes. J Biol Chem. 289:11443–11453. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yadav V, Sultana S, Yadav J and Saini N:
Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic
cancer cells via p21/p27/p53. PLoS One. 7:e477962012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khan M, Rasul A, Yi F, Zhong L and Ma T:
Jaceosidin induces p53-dependent G2/M phase arrest in U87
glioblastoma cells. Asian Pac J Cancer Prev. 12:3235–3238.
2011.PubMed/NCBI
|
|
23
|
Powell BL, van Staveren IL, Roosken P,
Grieu F, Berns EM and Iacopetta B: Associations between common
polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of
breast cancer. Carcinogenesis. 23:311–315. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darcy KM, Brady WE, McBroom JW, et al:
Associations between p53 overexpression and multiple measures of
clinical outcome in high-risk, early stage or
suboptimally-resected, advanced stage epithelial ovarian cancers A
Gynecologic Oncology Group study. Gynecol Oncol. 111:487–495. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Unoki M, Nishidate T and Nakamura Y:
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG
through its SRA domain. Oncogene. 23:7601–7610. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bostick M, Kim JK, Estève PO, Clark A,
Pradhan S and Jacobsen SE: UHRF1 plays a role in maintaining DNA
methylation in mammalian cells. Science. 317:1760–1764. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Achour M, Jacq X, Rondé P, et al: The
interaction of the SRA domain of ICBP90 with a novel domain of
DNMT1 is involved in the regulation of VEGF gene expression.
Oncogene. 27:2187–2197. 2008. View Article : Google Scholar
|
|
28
|
Achour M, Fuhrmann G, Alhosin M, et al:
UHRF1 recruits the histone acetyltransferase Tip60 and controls its
expression and activity. Biochem Biophys Res Commun. 390:523–528.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alhosin M, Sharif T, Mousli M,
Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB and Bronner C:
Down-regulation of UHRF1, associated with re-expression of tumor
suppressor genes, is a common feature of natural compounds
exhibiting anti-cancer properties. J Exp Clin Cancer Res.
30:412011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bronner C, Achour M, Arima Y, Chataigneau
T, Saya H and Schini-Kerth VB: The UHRF family: Oncogenes that are
drugable targets for cancer therapy in the near future. Pharmacol
Ther. 115:419–434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Unoki M, Brunet J and Mousli M: Drug
discovery targeting epigenetic codes: The great potential of UHRF1,
which links DNA methylation and histone modifications, as a drug
target in cancers and toxoplasmosis. Biochem Pharmacol.
78:1279–1288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JK, Estève PO, Jacobsen SE and Pradhan
S: UHRF1 binds G9a and participates in p21 transcriptional
regulation in mammalian cells. Nucleic Acids Res. 37:493–505. 2009.
View Article : Google Scholar :
|
|
33
|
Yamaguchi T, Cubizolles F, Zhang Y,
Reichert N, Kohler H, Seiser C and Matthias P: Histone deacetylases
1 and 2 act in concert to promote the G1-to-S progression. Genes
Dev. 24:455–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saldanha SN, Kala R and Tollefsbol TO:
Molecular mechanisms for inhibition of colon cancer cells by
combined epigenetic-modulating epigallocatechin gallate and sodium
butyrate. Exp Cell Res. 324:40–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tien AL, Senbanerjee S, Kulkarni A, et al:
UHRF1 depletion causes a G2/M arrest, activation of DNA damage
response and apoptosis. Biochem J. 435:175–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vijayaraghavalu S, Dermawan JK, Cheriyath
V and Labhasetwar V: Highly synergistic effect of sequential
treatment with epigenetic and anticancer drugs to overcome drug
resistance in breast cancer cells is mediated via activation of p21
gene expression leading to G2/M cycle arrest. Mol Pharm.
10:337–352. 2013. View Article : Google Scholar :
|
|
37
|
Zhang X, Li X, Zhang N, Yang Q and Moran
MS: Low doses ionizing radiation enhances the invasiveness of
breast cancer cells by inducing epithelial-mesenchymal transition.
Biochem Biophys Res Commun. 412:188–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsai JH, Hsu LS, Lin CL, Hong HM, Pan MH,
Way TD and Chen WJ: 3,5,4′-Trimethoxystilbene, a natural
methoxylated analog of resveratrol, inhibits breast cancer cell
invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin
signaling cascades and reversal of epithelial-mesenchymal
transition. Toxicol Appl Pharmacol. 272:746–756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo H, Wang L, Schulte BA, Yang A, Tang S
and Wang GY: Resveratrol enhances ionizing radiation-induced
premature senescence in lung cancer cells. Int J Oncol.
43:1999–2006. 2013.PubMed/NCBI
|
|
40
|
Hall EJ and Wuu CS: Radiation-induced
second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol
Biol Phys. 56:83–88. 2003. View Article : Google Scholar : PubMed/NCBI
|
